Publications by authors named "Raoul Tibes"

80Publications

Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.

Target Oncol 2020 04;15(2):147-162

Division of Hematology and Medical Oncology, New York University School of Medicine and Perlmutter Comprehensive Cancer Center, New York University Langone Health, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-020-00711-3DOI Listing
April 2020

Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.

Front Oncol 2019 12;9:1205. Epub 2019 Dec 12.

Mayo Clinic, Scottsdale, AZ, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.01205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920180PMC
December 2019

Triazolo[4,5]pyrimidines as Validated General Control Nonderepressible 2 (GCN2) Protein Kinase Inhibitors Reduce Growth of Leukemia Cells.

Comput Struct Biotechnol J 2018 28;16:350-360. Epub 2018 Sep 28.

Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S20010370183007
Publisher Site
http://dx.doi.org/10.1016/j.csbj.2018.09.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197744PMC
September 2018

All Thiopurines Are Equal But Some Thiopurines Are More Equal Than Others-Reply.

JAMA Oncol 2018 03;4(3):420-421

Division of Hematology and Medical Oncology, Mayo Clinic/Mayo Clinic Cancer Center, Phoenix, Arizona.

View Article

Download full-text PDF

Source
http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamaoncol.2017.3369DOI Listing
March 2018

Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.

JCO Precis Oncol 2017 1;2017. Epub 2017 Aug 1.

David L. Marks, Tara L. Hogenson, Anne M. Vrabel, Ashley N. Sigafoos, Ezequiel J. Tolosa, Ryan M. Carr, Stephanie L. Safgren, Elisa Enriquez Hesles, Luciana L. Almada, Paola A. Romecin-Duran, Eriko Iguchi, Aryan Ala'Aldeen, Jean-Pierre A. Kocher, Gavin R. Oliver, Naresh Prodduturi, David W. Mead, Asif Hossain, Norine E. Huneke, Colleen M. Tagtow, Sikander Ailawadhi, Stephen M. Ansell, Michaela S. Banck, Asher A. Chanan-Khan, Ronald S. Go, Thorvardur R. Halfdanarson, Richard W. Joseph, Prashant Kapoor, Aaron S. Mansfield, Amulya A. Nageswara Rao, Grzegorz S. Nowakowski, Animesh Pardanani, Sameer A. Parikh, John C. Cheville, Andrew L. Feldman, Ramesh K. Ramanathan, Steven I. Robinson, Heidi D. Finnes, Jennifer B. McCormick, Robert R. McWilliams, Aminah Jatoi, Mrinal M. Patnaik, Eric D. Wieben, Tammy M. McAllister, Kandelaria M. Rumilla, Sarah E. Kerr, Konstantinos N. Lazaridis, Gianrico Farrugia, Karl J. Clark, Eric W. Klee, and Martin E. Fernandez-Zapico, Mayo Clinic, Rochester; Ernesto Resnik, Bio-Techne, Minneapolis, MN; Sikander Ailawadhi, Asher A. Chanan-Khan, and Richard W. Joseph, Mayo Clinic, Jacksonville, FL; Jan B. Egan, Alan H. Bryce, Estrella M. Carballido, KellyK. Curtis, Chelsea D. Gawryletz, Thai H. Ho,Nathalie Meurice, Ramesh K. Ramanathan, Raoul Tibes, Alvin C. Silva, A. Keith Stewart, and Mitesh J. Borad, Mayo Clinic, Phoenix, AZ; and Eileen J. Kennedy, University of Georgia, Athens, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.17.00018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369924PMC
August 2017

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.

J Natl Compr Canc Netw 2016 12;14(12):1505-1512

From St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Memorial Sloan Kettering Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Stanford Cancer Institute; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Vanderbilt-Ingram Cancer Center; The University of Texas MD Anderson Cancer Center; Fox Chase Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; Roswell Park Cancer Institute; University of Colorado Cancer Center; University of Michigan Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; UCSF Helen Diller Family Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; City of Hope Comprehensive Cancer Center; Moffitt Cancer Center; Mayo Clinic Cancer Center; University of Wisconsin Carbone Cancer Center; National Comprehensive Cancer Network; Huntsman Cancer Institute at the University of Utah; and Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0162DOI Listing
December 2016

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 12 31;34(36):4371-4380. Epub 2016 Oct 31.

Suzanne Leijen, Robin M.J.M. van Geel, and Jan H.M. Schellens, The Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands; Anna C. Pavlick, New York University Medical Center, New York, NY; Lee Rosen, University of California Los Angeles, Santa Monica, CA; Raymond Lam, Shelonitda Rose, Mark A. Lee, Tomoko Freshwater, and Stuart Shumway, Merck, Kenilworth, NJ; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Albiruni R. Abdul Razak and Amit M. Oza, Princess Margaret Hospital, Toronto, Ontario, Canada; Raoul Tibes, University Hospital of Würzburg, Würzburg; Tim Demuth, Sandoz AG, Holzkirchen, Germany; and Li Wen Liang, Merck Sharp & Dohme R&D, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.5991DOI Listing
December 2016

Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.

Oncotarget 2016 Jan;7(2):1927-46

Department of Molecular Pharmacology and Experimental Therapeutics and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.6481DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811507PMC
January 2016

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.

J Hematol Oncol 2015 Oct 20;8:114. Epub 2015 Oct 20.

Division of Hematology and Medical Oncology, Mayo Clinic/Mayo Clinic Cancer Center, 13400 E. Shea Boulevard, Scottsdale, AZ, 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-015-0211-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615363PMC
October 2015

Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapy.

Cancer Epidemiol 2015 Dec 11;39(6):1084-92. Epub 2015 Sep 11.

Division of Hematology and Medical Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canep.2015.09.003DOI Listing
December 2015

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.

J Hematol Oncol 2014 Mar 5;7:18. Epub 2014 Mar 5.

Mayo Clinic Cancer Center, NCI Designated Comprehensive Cancer Center, 13400 E, Shea Blvd, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1756-8722-7-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975838PMC
March 2014

Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

J Natl Cancer Inst 2014 Feb;106(2):djt440

Affiliations of authors: Section of Molecular Hematology and Therapy, Department of Leukemia (BZC, PYM, DHM, YS, YQ, HM, ROJ, TM, SMK, MA) and Department of Bioinformatics and Computational Biology (HY, KRC), University of Texas M.D. Anderson Cancer Center, Houston, TX; Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ (JMB, RT).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt440DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952202PMC
February 2014

Emerging drugs for polycythemia vera.

Expert Opin Emerg Drugs 2013 Sep;18(3):393-404

Mayo College of Medicine, Mayo Clinic, Mayo Clinic Cancer Center, Division of Hematology & Medical Oncology, 13400 E. Shea Boulevard, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.2013.832754DOI Listing
September 2013

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib.

Cancer Med 2012 Oct 17;1(2):230-6. Epub 2012 Sep 17.

Scottsdale Medical Imaging, Ltd. Scottsdale, AZ; Midwestern University Glendale, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.33DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544445PMC
October 2012

JAK inhibition: the key to treating myeloproliferative neoplasm?

Expert Rev Hematol 2012 Dec;5(6):583-5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.12.55DOI Listing
December 2012

Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.

Mol Diagn Ther 2012 Oct;16(5):269-83

Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40291-012-0006-3DOI Listing
October 2012

MPN blast phase: clinical challenge and assessing response.

Leuk Res 2012 Dec 19;36(12):1496-7. Epub 2012 Sep 19.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.08.026DOI Listing
December 2012

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

Expert Opin Investig Drugs 2012 Dec 19;21(12):1755-74. Epub 2012 Sep 19.

Mayo Clinic, Hematology, 200 First Street SW, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2012.721352DOI Listing
December 2012

JAK2 inhibitors and their impact in myeloproliferative neoplasms.

Hematology 2012 Apr;17 Suppl 1:S129-32

Department of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1179/102453312X13336169156375DOI Listing
April 2012

Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques.

Leuk Res 2012 Jun 28;36(6):664-71. Epub 2012 Mar 28.

Mayo Clinic, Scottsdale, AZ 85259, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.02.027DOI Listing
June 2012

RNAi screening of the kinome with cytarabine in leukemias.

Blood 2012 Mar 20;119(12):2863-72. Epub 2012 Jan 20.

Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-07-367557DOI Listing
March 2012

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?

Curr Hematol Malig Rep 2012 Mar;7(1):78-86

Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-011-0107-9DOI Listing
March 2012

Activity of alemtuzumab in acute myelogenous leukemia and myelodysplastic syndrome with chromosome 7 aberrations.

J Clin Oncol 2011 Dec 14;29(36):4841-2; author reply 4842. Epub 2011 Nov 14.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.38.4602DOI Listing
December 2011

Blood consult: resistant and progressive essential thrombocythemia.

Blood 2011 Jul 23;118(2):240-2. Epub 2011 May 23.

Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-01-327213DOI Listing
July 2011

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?

Leuk Lymphoma 2011 Jul 23;52(7):1178-87. Epub 2011 May 23.

Department of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2011.566952DOI Listing
July 2011

Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials.

Cancer 2011 Jul 18;117(14):3276-83. Epub 2011 Jan 18.

Translational Genomics Research Institute and Virginia G. Piper Cancer Center, Phoenix/Scottsdale, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25885DOI Listing
July 2011

Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma.

Laryngoscope 2010 Dec;120(12):2456-9

Department of Head and Neck Surgery, Kaiser Permanente Medical Center, Oakland, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lary.21145DOI Listing
December 2010

RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.

Gynecol Oncol 2010 Sep;118(3):220-7

Pharmaceutical Genomics Division, The Translational Genomics Research Institute, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2010.05.006DOI Listing
September 2010

RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.

Mol Cancer 2010 Aug 18;9:218. Epub 2010 Aug 18.

Pharmaceutical Genomic Division, Translational Genomics Research Institute, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-9-218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933621PMC
August 2010

Functional proteomic profiling of AML predicts response and survival.

Blood 2009 Jan 7;113(1):154-64. Epub 2008 Oct 7.

Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2007-10-119438DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951831PMC
January 2009

PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation.

Br J Haematol 2008 Feb 5;140(3):344-7. Epub 2007 Dec 5.

Pharmaceutical Genomics Division, The Translational Genomics Research Institute (TGen), Phoenix/Scottsdale, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2007.06920.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385948PMC
February 2008

Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells.

Mol Cancer Ther 2006 Oct;5(10):2512-21

Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-06-0334DOI Listing
October 2006

Activity of alemtuzumab in patients with CD52-positive acute leukemia.

Cancer 2006 Jun;106(12):2645-51

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.21901DOI Listing
June 2006

Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.

Annu Rev Pharmacol Toxicol 2005 ;45:357-84

Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev.pharmtox.45.120403.100124DOI Listing
May 2005